EcoDrugPlus

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSLCRG00005006955
Gene Symbol: AXL
3 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLCRG00005006476
Gene Symbol: BRAF
3 Cross references
217 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSLCRG00005018323
Gene Symbol: LOC113744632
2 Cross references
247 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSLCRG00005018324
Gene Symbol: LOC104924151
2 Cross references
247 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSLCRG00005011561
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSLCRG00005022371
Gene Symbol: SI:DKEY-91M11.5
3 Cross references
196 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSLCRG00005004556
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSLCRG00005011341
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-X-C Chemokine Receptor Type 4

Ensembl ID : ENSLCRG00005009998
Gene Symbol: LOC104926341
3 Cross references
201 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSLCRG00005007342
Gene Symbol: LOC104940317
2 Cross references
408 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSLCRG00005018178
Gene Symbol: LOC104940052
2 Cross references
359 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLCRG00005002834
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).